Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors
© Landais et al; licensee BioMed Central Ltd. 2009
Received: 24 September 2009
Accepted: 31 December 2009
Published: 31 December 2009
The Fanconi anemia (FA) pathway is a multigene DNA damage response network implicated in the repair of DNA lesions that arise during replication or after exogenous DNA damage. The FA pathway displays synthetic lethal relationship with certain DNA repair genes such as ATM (Ataxia Telangectasia Mutated) that are frequently mutated in tumors. Thus, inhibition of FANCD2 monoubiquitylation (FANCD2-Ub), a key step in the FA pathway, might target tumor cells defective in ATM through synthetic lethal interaction. Curcumin was previously identified as a weak inhibitor of FANCD2-Ub. The aim of this study is to identify derivatives of curcumin with better activity and specificity.
Using a replication-free assay in Xenopus extracts, we screened monoketone analogs of curcumin for inhibition of FANCD2-Ub and identified analog EF24 as a strong inhibitor. Mechanistic studies suggest that EF24 targets the FA pathway through inhibition of the NF-kB pathway kinase IKK. In HeLa cells, nanomolar concentrations of EF24 inhibited hydroxyurea (HU)-induced FANCD2-Ub and foci in a cell-cycle independent manner. Survival assays revealed that EF24 specifically sensitizes FA-competent cells to the DNA crosslinking agent mitomycin C (MMC). In addition, in contrast with curcumin, ATM-deficient cells are twofold more sensitive to EF24 than matched wild-type cells, consistent with a synthetic lethal effect between FA pathway inhibition and ATM deficiency. An independent screen identified 4H-TTD, a compound structurally related to EF24 that displays similar activity in egg extracts and in cells.
These results suggest that monoketone analogs of curcumin are potent inhibitors of the FA pathway and constitute a promising new class of targeted anticancer compounds.
Fanconi anemia (FA) is a multigene genetic disease characterized by developmental defects, early bone marrow failure and genomic instability leading to a high incidence of cancers . At the molecular level, the FA pathway is a highly integrated DNA damage response network of proteins implicated in the repair of various DNA lesions and particularly DNA interstrand crosslinks [2, 3]. The pathway is composed of a core complex of at least 10 proteins (including FANCA, B, C, E, F, G, L, M, FAAP24 and FAAP100) that function as an E3 ubiquitin ligase for the monoubiquitylation and activation of FANCD2 and FANCI . Downstream proteins such as FANCD1/BRCA2, FANCJ/BRIP1 and FANCN/PALB2 have been linked to elevated risk of breast and ovarian cancers . However, although the FA pathway is well-defined biochemically, its precise roles in the DNA damage response remain obscure.
The FA pathway is a potential target in anticancer therapy either through chemosensitization of tumor cells to DNA crosslinking agents such as melphalan and cisplatin [5, 6] or by exploiting synthetic lethal interactions. Two genes have a synthetic lethal relationship if mutants for either gene are viable but the double mutation is lethal . Targeting this particular type of genetic interaction in tumors is currently the subject of intense development due to the promising results of clinical trials using PARP inhibitors in BRCA1/2-deficient breast tumors [8, 9]. High-throughput screens to identify genes displaying synthetic lethal interaction with genes frequently impaired in tumors are demonstrating the potential for discovering functional dependencies created by oncogenic mutations that may enable therapeutic intervention for cancers with "undruggable" genetic alterations such as RAS [10, 11]. With regard to FA, D'Andrea and coworkers identified a set of DNA damage response genes required for the survival of FA-deficient cells including ATM (Ataxia Telangectasia Mutated). ATM is a major kinase involved in the sensing and repair of DNA double-strand breaks by homologous recombination . Germline mutations in this gene cause the Ataxia Telangectasia cancer susceptibility syndrome , and ATM deficiencies (mutations or lack of expression) are also frequent in sporadic hematological malignancies such as chronic lymphocytic leukemia  and mantle cell lymphoma . Because deficiency in the FA pathway is not lethal , specific inhibitors are expected to display low toxicity toward normal cells but kill tumor cells deficient in ATM or other genes with synthetic lethal relationships to the FA pathway.
A cell-based screen for inhibitors of FANCD2 monoubiquitylation (FANCD2-Ub) recently identified curcumin , a phytochemical with anticancer properties that have been linked to a variety of mechanisms including apoptosis through the NFκB pathway . Efforts to develop curcumin analogs with improved solubility, stability and activity have led to the generation of a series of monoketone derivatives including EF24, a strong candidate for further drug development in cancer therapy [18–22]. We evaluated these curcumin analogs in a cell-free assay that uses Xenopus egg extracts to uncouple FANCD2-Ub from ongoing replication [6, 23–26]. The most active compounds were subsequently tested in mammalian cells for FA pathway inhibition and synthetic lethal interactions.
Inhibition of xFANCD2-Ub by monoketone analogs of curcumin in Xenopus extracts
Mechanism of xFANCD2-Ub inhibition by EF24
To explore potential mechanisms by which curcumin analogs inhibit the FA pathway, we evaluated the integrity of the FA core complex in Xenopus extracts containing EF24, one of the most active analogs. In human cells, hFANCD2-Ub is reduced when FA core complex proteins are defective or absent. However we found that the integrity of the core complex was unchanged in the presence or absence of EF24 (Additional File 1 - Fig. S1). Next, we found that EF24 did not detectably interfere with the recruitment of the core complex to DNA, a crucial step for xFANCD2 activation in Xenopus extracts (data not shown, ).
EF24 inhibits hFANCD2-Ub and hFANCD2 foci in HeLa cells
As the activity of the FA pathway is cell cycle dependent, we monitored the effect of HU and EF24 on the cell cycle by FACS analysis. We found no significant change in the cell cycle profile of cells treated with HU in combination with EF24 compared to that of untreated cells (Additional File 1 - Fig. S2), suggesting that EF24 does not inhibit hFANCD2-Ub through perturbation of the cell cycle.
To confirm inhibition of the FA pathway using another readout, we monitored the effect of EF24 on HU-induced hFANCD2 foci in HeLa cells (Fig. 4B) . IC50 values for inhibition of foci formation were in the same range as IC50 values for hFANCD2-Ub inhibition, an expected result since hFANCD2-Ub but not the unmodified hFANCD2 is competent to form foci .
EF24 sensitizes FA-competent cells to mitomycin C (MMC)
We tested whether EF24 is a specific inhibitor of the FA pathway by comparing its effect on a FANCA-deficient cell line (HSC72OT) and its complemented, wild-type-like counterpart (HSC72OT+A)  in the presence of the DNA crosslinking agent MMC. If EF24 specifically targets the FA pathway, it should sensitize FA-competent cells to MMC but not FA-deficient cells.
Sensitivity of ATM-deficient cells to EF24 suggests a synthetic lethal effect
These results suggest that the toxicity of EF24 observed in ATM-deficient cells may be caused by a synthetic lethal effect due to the inhibition of the FA pathway in the absence of ATM.
4H-TTD, a novel curcumin analog with properties similar to EF24
These results underscore the use of Xenopus egg extracts as a useful screening strategy to rapidly identify inhibitors of the FA pathway and further validates this class of compounds as potent FA pathway inhibitors and potential anticancer agents for synthetic lethal relationship-based targeted therapy.
DNA damage response pathways have recently been the target of considerable efforts in oncology research. This is due in part to the successful treatment of BRCA-deficient tumors with PARP1 inhibitors [8, 9], which demonstrated that taking advantage of the synthetic lethal relationship between two DNA damage genes is a valid approach for the development of novel targeted therapies in oncology . Two parameters are important for a synthetic lethal interaction to be exploited therapeutically against cancers: first, functional deficiency of one of the genes has to be a causative event of the tumorigenesis. Impairment of DNA damage responses, which is strongly suspected to be one of the most common initial event during tumorigenesis , fits this requirement. The second condition is that the target of the therapeutic agent is not an essential gene, hence limiting toxicity and increasing the therapeutic window. Many DNA damage response pathways are partially redundant, explaining why one defect is usually well tolerated at least in the short term, e.g. PARP1 [7, 38].
Synthetic lethal interactions between the FA pathway and other DNA damage response genes such as ATM, PARP1 and NBS1 have been identified recently , stimulating interest in determining if FA pathway inhibitors would selectively target tumor cells deficient in these genes. For instance, ATM mutations are highly prevalent (approx. 50%) in mantle cell lymphoma patients , raising the possibility that these tumors might be selectively treated with a FA pathway inhibitor.
The first identified FA pathway inhibitor was curcumin . To improve potency and specificity, we compared the FA pathway inhibition activity of a series of monoketone analogs of curcumin  in Xenopus extracts, and identified EF24 and 4 other compounds as potent FA pathway inhibitors. Similar to DDN and other inhibitors we previously identified  and data not shown), curcumin analogs displayed similar activity against MRE11 phosphorylation but did not inhibit RPA32 and H2AX phosphorylation. This finding will be important practically for the design of a high-throughput assay, allowing rapid discrimination between specific FA pathway inhibitors and those that also inhibit MRE11 phosphorylation.
Structural similarity of EF24 and 4H-TTD confirmed that monoketone analogs of curcumin form a new class of FA pathway inhibitors. Within the same structural template, heteroatom ring replacements and a subset of terminal aromatic ring substituents appear to account for the potency of a given compound. With respect to the central six-membered ketone for example, the piperidone derivatives (EF24, EF31, AS153-4, and AS153-5) are much more potent than the corresponding thio-pyran analog (AS153-1). However, decorating the nitrogen of the piperidone with a strong electron withdrawing group that diminishes the basicity of the nitrogen, for instance the Boc group, causes complete loss of activity (0616-104). Switching from piperidone to pyran or cyclohexanone likewise decreases activity to undetectable levels in Xenopus extracts (AS153-2 and 0810-117). By contrast, the central sulfone of 4H-TTD restores activity perhaps by virtue of its unique ability to serve as a proton acceptor on both faces of the central ring. With respect to terminal ring substitution, the moieties that deliver the most potent analogs are F, OH and the pyridine nitrogen (Fig. 1) . Aromatic nitro groups coupled with a central ring sulfone as represented by 4H-TTD (Fig. 7A) represents a novel combination. This emerging SAR provides a direction for further optimization. For example, it will be instructive to see if combining nitro groups with a piperidone ring or fluoro substituents with sulfone will either match or enhance the observed activities.
While exploring the mechanism of FA pathway inhibition, we found that EF24 is a weak proteasome inhibitor. The more effective proteasome inhibition by curcumin (Fig. 2) may be due to structural features absent in the monocarbonyl analogs. Three prominent structural elements that differentiate the two chemical classes are the central rigidifying ring in the analogs, the presence of the central three-carbon unit bearing two oxygens and the phenolic oxygens in curcumin. The antioxidant properties of curcumin are generally attributed to the radical scavenging abilities of the phenolic OH groups  and the central 1,3-diketone functionality . Thus, either radical scavenging or a change in molecular architecture or both may be the basis for curcumin's superior activity against the proteasome. This result implies that EF24 has a spectrum of activities narrower than curcumin.
Inhibition of the FA pathway in cells
With activity in the nanomolar range in cells, EF24 and 4H-TTD are the most active FA pathway inhibitor identified so far [5, 6, 30]. As previously noted , EF24 and 4H-TTD effective concentrations were 2 to 3 orders of magnitude lower in cells than in extracts, probably because of the strong quenching occurring in extracts due to high proteins and lipids content .
We next tested whether inhibition of the FA pathway by EF24 could be exploited to target cells using sensitization and synthetic lethal interaction approaches. Using a combination strategy , we found that a non-toxic dose of EF24 sensitized FA-competent cells to the DNA crosslinking agent MMC. EF24 failed to sensitize isogenic FA-deficient cells to MMC, suggesting that inhibition of the FA pathway rather than pleiotropic activity was responsible for the sensitization phenotype observed (Fig. 5). Hence EF24 might be an interesting lead as a chemosensitizer for DNA crosslinking agents such as MMC and platinium compounds.
Next, EF24 and 4H-TTD were used as single agents in congenic cell lines differing in their ATM status. We found that both compounds were significantly more toxic to ATM KO cells than WT cells. These results are consistent with a model where inhibition of the FA pathway by curcumin analogs triggered a synthetic lethal effect in ATM-deficient cells . The failure of curcumin to display the same effect could be due to the fact that its weak activity against the FA pathway is masked by the activity toward numerous other targets, for instance the proteasome.
Mechanism of FA pathway inhibition
EF24 did not inhibit the FA pathway by well-known mechanisms such as disrupting the integrity of the FA core complex , impairement of recruitment of FA proteins to DNA substrates  or proteasome inhibition . Surprisingly, proteasome inhibition did not affect xFANCD2-Ub in Xenopus extracts, suggesting that the proteasome is not involved in the basic activation of the FA pathway. Rather, it may be required in the more complex cellular environment to overcome the chromatin barrier or to respond to specific DNA lesions . Importantly, this finding further highlights the use of the Xenopus extracts-based screening assay to identify compounds that are more likely to target the core FA pathway rather than general regulators. Underscoring this notion, monoubiquitylation of FANCD2 is also independent of phosphorylation in DNA-stimulated extracts (Fig. 3C ).
Interestingly, Aleo E. et al  identified 4H-TTD (called "G5" in their work) in a screen for compounds that trigger caspase activation in a BCL-2 dependent and caspase 9-independent manner. 4H-TTD did not inhibit proteasome activity, confirming the data obtained with EF24 and related analogs. Instead, 4H-TTD exhibited ubiquitin isopeptidase/deubiquitinase (DUB) inhibition activity. Structural analysis further revealed a molecular determinant shared with known ubiquitin isopeptidase inhibitors  that is also present in EF24, raising the possibility that monoketone analogs of curcumin could inhibit FANCD2- Ub through a novel mechanism involving DUB inhibition independently of the proteasome.
During this study, we found that EF24 inhibits the phosphorylation of xMRE11 and xFANCM in Xenopus extracts (Fig. 1, 3 and Additional File 1 - Fig S1). Since both proteins are the target of the DNA damage signaling and checkpoint kinases ATM and ATR [28, 44], we tested whether EF24 treatment affected the phosphorylation status of a classic ATR target, CHK1 . Reprobing the EF24 blot shown in Fig. 7B with a phospho-CHK1-specific antibody revealed that CHK1-P was inhibited at the highest EF24 concentration tested (400 mM, Additional File 1 - Fig. S4), suggesting that this curcumin analog is a bona fide but weak ATR inhibitor. Since FANCD2 monoubiquitylation has been shown to be dependent on ATR both in mammalian cells [46, 47] and in replicating Xenopus extracts [23, 26, 44], it was therefore tempting to hypothesize that EF24 inhibits FANCD2-Ub through ATR inhibition. However our lab has clearly demonstrated that FANCD2-Ub is not dependent on ATR in non-replicating, DNA substrate-stimulated extracts: chemical inhibition of ATR by caffeine or depletion of ATR and its essential partner ATRIP have no detectable effect on FANCD2-Ub in this setting (Fig. 3C and [24, 44]). Taken together, these data suggest that EF24 might be a weak ATR inhibitor, but this activity does not account for FANCD2-Ub inhibition in non-replicating extracts.
An alternative hypothesis emerged from the fact that one of the cellular targets of curcumin and EF24 is the IκB kinase complex (IKK), a major component of the NF-κB pathway. Otsuki et al  showed that IKK interacts with the FA core complex, raising the possibility that EF24 might inhibit the FA pathway by targeting IKK. This hypothesis is in line with the fact that curcumin has a weaker inhibitory activity than EF24 toward both IKK and xFANCD2-Ub (Fig. 1, Fig. 4 and ). Interestingly, we found that the specific IKK inhibitor BMS-345541  inhibited xFANCD2-Ub in a manner similar to EF24, i.e. xFANCD2-Ub inhibition occurred at higher concentration than IkB-α stabilization (Fig 3A, B). This differential effect is reminiscent of the fact that BMS-345541 is 10-fold more active on IKK-2 (IKKβ) than on IKK-1 (IKKα), maybe because allosteric binding induces a different conformational change in the two IKK subunits . The latter result also suggests that the kinase activity of IKK is not required for plasmid activation of the FA pathway in extracts. The fact that general phosphorylation modulators did not interfere with EF24 (Fig. 3C) provided an indirect confirmation of this hypothesis. Additional experiments are needed to explore the potential link between EF24, IKK and the FA pathway.
Like curcumin, the mimics depicted in Figure 1 are pleiotropic agents with activities as diverse as mitochondrial redox-mediators , tubulin dynamics disrupters , kinase inhibitors , glioma cell radiosensitizers  and angiogenesis blockers . Although their multiplicity of actions is complex, predictive pharmacological models  and optimization  are emerging within systems biology. The discovery that monoketone analogs of curcumin form a new class of FA pathway inhibitors not only underscores their potential for low toxicity targeted cancer therapy, it also adds to the still incomplete network of beneficial biological actions exerted by these multi-tasking agents.
To our knowledge, this is the first report suggesting that small molecule inhibition of the FA pathway may specifically target ATM-deficient cells. Additional experiments are under way to confirm this synthetic lethal effect and to test whether these compounds are effective in human ATM-deficient cancer cells as well.
Chemicals and antibodies
Monoketone analogs of curcumin were prepared as previously described . Pure curcumin, MG132 (Calbiochem), IKK inhibitor III (BMS-345541, Calbiochem), DRB (Calbiochem), 4H-TTD (NSC 144303, NCI/DTP Open Chemical Repository, http://dtp.nci.nih.gov) were resuspended in DMSO, tautomycin (Calbiochem) in EtOH, caffeine and hydroxyurea (Sigma) in H2O. Shrimp alkaline phosphatase was from Fermentas. Antibodies against xFANCD2, xFANCG, xFANCA and hFANCD2 were described previously . Antibodies against γH2AX and IkB-α were from Bethyl laboratories (#A300-081A) and cell Signaling (#9242), respectively. Antibodies against xRPA, xMre11 and hFANCD2 (for immunofluorescence) were kind gifts of K. Cimprich, J. Gautier and K.J. Patel, respectively.
Xenopus cell-free assay and immunoblotting
Preparation of Xenopus laevis low-speed extracts and the FA pathway assay were described previously .
Fluorogenic peptides (Proteasome Substrate Pack #PW9905) specific for the chymotrypsin-like and caspase-like activities of the proteasome were incubated in Xenopus extracts treated with serial dilutions of various compounds. Fluorescence emitted by proteasome cleavage of the peptides was monitored using a fluorometer (FluoStar Galaxy, BMG Labtech) with 380 nm and 460 nm excitation and emission filters, respectively. Experiments were repeated at least twice. Due to the large variability of activity between extract batches, one representative experiment is shown.
Cell lines and cell culture
HeLa cells were grown in DMEM medium supplemented with 10% serum in humidified 5% CO2 atmosphere. ATM-deficient and ATM-proficient kidney cells from congenic adult mice (309ATM KO and 334ATM WT)  were grown in the same medium.
hFANCD2 ubiquitylation assay and immunofluorescence microscopy in HeLa cells
hFANCD2 ubiquitylation assay and immunofluorescence assays in HeLa cells have been described elsewhere .
HSC72OT and HSC72OT+A cells were seeded at 5,000 per well in 96-well plates, and treated 24 hrs later with various concentrations of compounds or DMSO (1 μl in 100 μl medium). 309ATM KO and 334ATM WT cells were seeded at 7,000 per well and treated immediately. Cell survival was measured after 3 days using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) following the recommendations from the manufacturer. All experiments were done in triplicate.
Calculation of IC50 values
Fitted curves were determined from experimental data using IgorPro. The concentration of compound that induces 50% inhibition of the measured endpoint (i.e. FANCD2 ubiquitylation, Mre11 phosphorylation and cell survival) was then plotted on the fitted curve.
We thank Dr. K. Cimprich, Dr. J. Gautier and Dr K.J. Patel for generously sharing antibodies for xRPA, xMre11 and hFANCD2, respectively. We are grateful to Marion Lanier, from the Human BioMolecular Research Institute, for chemical structure analysis and to Professor Dennis Liotta (Emory University) for encouragement and support. Financial support: M. Hoatlin (NIH CA112775, OHSU BioScience Innovation Fund Grant and the Fanconi Anemia Research Fund (FARF); I. Landais (NRSA postdoctoral training grant CA101690-03).
- Kalb R, Neveling K, Nanda I, Schindler D, Hoehn H: Fanconi anemia: causes and consequences of genetic instability. Genome Dyn. 2006, 1: 218-242.View ArticlePubMed
- de Winter JP, Joenje H: The genetic and molecular basis of Fanconi anemia. Mutat Res. 2008
- Wang W: Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007, 8: 735-748. 10.1038/nrg2159View ArticlePubMed
- Rahman N, Scott RH: Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet. 2007, 16 (Spec No 1): R60-66. 10.1093/hmg/ddm026View ArticlePubMed
- Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD: Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006, 5: 952-961. 10.1158/1535-7163.MCT-05-0493View ArticlePubMed
- Landais I, Sobeck A, Stone S, LaChapelle A, Hoatlin ME: A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway. Int J Cancer. 2009, 124: 783-792. 10.1002/ijc.24039View ArticlePubMed
- Ashworth A: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008, 26: 3785-3790. 10.1200/JCO.2008.16.0812View ArticlePubMed
- Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009, 361: 123-134. 10.1056/NEJMoa0900212View ArticlePubMed
- Tuma RS: PARP inhibitors: will the new class of drugs match the hype?. J Natl Cancer Inst. 2009, 101: 1230-1232. 10.1093/jnci/djp315View ArticlePubMed
- Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009, 137: 821-834. 10.1016/j.cell.2009.03.017View ArticlePubMed
- Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009, 137: 835-848. 10.1016/j.cell.2009.05.006PubMed CentralView ArticlePubMed
- Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA, Shimamura A, D'Andrea AD: Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest. 2007, 117: 1440-1449. 10.1172/JCI31245PubMed CentralView ArticlePubMed
- Czornak K, Chughtai S, Chrzanowska KH: Mystery of DNA repair: the role of the MRN complex and ATM kinase in DNA damage repair. J Appl Genet. 2008, 49: 383-396. 10.1007/BF03195638View ArticlePubMed
- Lavin MF: Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 2008, 9: 759-769. 10.1038/nrm2514View ArticlePubMed
- Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, Majid A, Dyer M, Siebert R, Taylor AM: Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007, 25: 5448-5457. 10.1200/JCO.2007.11.2649View ArticlePubMed
- Fang NY, Greiner TC, Weisenburger DD, Chan WC, Vose JM, Smith LM, Armitage JO, Mayer RA, Pike BL, Collins FS, Hacia JG: Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci USA. 2003, 100: 5372-5377. 10.1073/pnas.0831102100PubMed CentralView ArticlePubMed
- Aggarwal BB, Sundaram C, Malani N, Ichikawa H: Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007, 595: 1-75.View ArticlePubMed
- Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR: Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem. 2004, 12: 3871-3883. 10.1016/j.bmc.2004.05.006View ArticlePubMed
- Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, Sun A, Snyder JP, Liotta DC, Jones DP, Shoji M: EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs. 2005, 16: 263-275. 10.1097/00001813-200503000-00005View ArticlePubMed
- Sun A, Shoji M, Lu YJ, Liotta DC, Snyder JP: Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem. 2006, 49: 3153-3158. 10.1021/jm051141kView ArticlePubMed
- Shoji M, Sun A, Kisiel W, Lu YJ, Shim H, McCarey BE, Nichols C, Parker ET, Pohl J, Mosley CA: Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target. 2008, 16: 185-197. 10.1080/10611860801890093View ArticlePubMed
- Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E, Giannakakou P: EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle. 2008, 7: 2409-2417.PubMed CentralView ArticlePubMed
- Sobeck A, Stone S, Costanzo V, de Graaf B, Reuter T, de Winter J, Wallisch M, Akkari Y, Olson S, Wang W: Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. Mol Cell Biol. 2006, 26: 425-437. 10.1128/MCB.26.2.425-437.2006PubMed CentralView ArticlePubMed
- Sobeck A, Stone S, Hoatlin ME: DNA structure-induced recruitment and activation of the Fanconi anemia pathway protein FANCD2. Mol Cell Biol. 2007, 27: 4283-4292. 10.1128/MCB.02196-06PubMed CentralView ArticlePubMed
- Ben-Yehoyada M, Wang LC, Kozekov ID, Rizzo CJ, Gottesman ME, Gautier J: Checkpoint signaling from a single DNA interstrand crosslink. Mol Cell. 2009, 35: 704-715. 10.1016/j.molcel.2009.08.014PubMed CentralView ArticlePubMed
- Wang LC, Stone S, Hoatlin ME, Gautier J: Fanconi anemia proteins stabilize replication forks. DNA Repair (Amst). 2008, 7: 1973-1981. 10.1016/j.dnarep.2008.08.005View Article
- Costanzo V, Robertson K, Bibikova M, Kim E, Grieco D, Gottesman M, Carroll D, Gautier J: Mre11 protein complex prevents double-strand break accumulation during chromosomal DNA replication. Mol Cell. 2001, 8: 137-147. 10.1016/S1097-2765(01)00294-5View ArticlePubMed
- Di Virgilio M, Ying CY, Gautier J: PIKK-dependent phosphorylation of Mre11 induces MRN complex inactivation by disassembly from chromatin. DNA Repair (Amst). 2009
- Lupardus PJ, Byun T, Yee MC, Hekmat-Nejad M, Cimprich KA: A requirement for replication in activation of the ATR-dependent DNA damage checkpoint. Genes Dev. 2002, 16: 2327-2332. 10.1101/gad.1013502PubMed CentralView ArticlePubMed
- Jacquemont C, Taniguchi T: Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res. 2007, 67: 7395-7405. 10.1158/0008-5472.CAN-07-1015View ArticlePubMed
- Jana NR, Dikshit P, Goswami A, Nukina N: Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem. 2004, 279: 11680-11685. 10.1074/jbc.M310369200View ArticlePubMed
- Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri FR, Wang CY, Shoji M, Sun A, Snyder JP: Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3, 5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol. 2008, 74: 654-661. 10.1124/mol.108.046201PubMed CentralView ArticlePubMed
- Otsuki T, Young DB, Sasaki DT, Pando MP, Li J, Manning A, Hoekstra M, Hoatlin ME, Mercurio F, Liu JM: Fanconi anemia protein complex is a novel target of the IKK signalsome. J Cell Biochem. 2002, 86: 613-623. 10.1002/jcb.10270View ArticlePubMed
- Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J: BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem. 2003, 278: 1450-1456. 10.1074/jbc.M209677200View ArticlePubMed
- Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD: S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood. 2002, 100: 2414-2420. 10.1182/blood-2002-01-0278View ArticlePubMed
- Duckworth-Rysiecki G, Cornish K, Clarke CA, Buchwald M: Identification of two complementation groups in Fanconi anemia. Somat Cell Mol Genet. 1985, 11: 35-41. 10.1007/BF01534732View ArticlePubMed
- Rai R, Peng G, Li K, Lin SY: DNA damage response: the players, the network and the role in tumor suppression. Cancer Genomics Proteomics. 2007, 4: 99-106.PubMed
- Wang ZQ, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K, Wagner EF: PARP is important for genomic stability but dispensable in apoptosis. Genes Dev. 1997, 11: 2347-2358. 10.1101/gad.11.18.2347PubMed CentralView ArticlePubMed
- Ak T, Gulcin I: Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact. 2008, 174: 27-37. 10.1016/j.cbi.2008.05.003View ArticlePubMed
- Patro BS, Rele S, Chintalwar GJ, Chattopadhyay S, Adhikari S, Mukherjee T: Protective activities of some phenolic 1, 3-diketones against lipid peroxidation: possible involvement of the 1, 3-diketone moiety. Chembiochem. 2002, 3: 364-370. 10.1002/1439-7633(20020402)3:4<364::AID-CBIC364>3.0.CO;2-SView ArticlePubMed
- Dupre A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, Nicolette ML, Kopelovich L, Jasin M, Baer R, Paull TT, Gautier J: A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2008, 4: 119-125. 10.1038/nchembio.63PubMed CentralView ArticlePubMed
- Gurtan AM, Stuckert P, D'Andrea AD: The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly. J Biol Chem. 2006, 281: 10896-10905. 10.1074/jbc.M511411200View ArticlePubMed
- Aleo E, Henderson CJ, Fontanini A, Solazzo B, Brancolini C: Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res. 2006, 66: 9235-9244. 10.1158/0008-5472.CAN-06-0702View ArticlePubMed
- Sobeck A, Stone S, Landais I, de Graaf B, Hoatlin ME: The Fanconi anemia protein FANCM is controlled by FANCD2 and the ATR/ATM pathways. J Biol Chem. 2009, 284: 25560-25568. 10.1074/jbc.M109.007690PubMed CentralView ArticlePubMed
- Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A: Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000, 14: 1448-1459. 10.1101/gad.840500PubMed CentralView ArticlePubMed
- Ho GP, Margossian S, Taniguchi T, D'Andrea AD: Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol. 2006, 26: 7005-7015. 10.1128/MCB.02018-05PubMed CentralView ArticlePubMed
- Ishiai M, Kitao H, Smogorzewska A, Tomida J, Kinomura A, Uchida E, Saberi A, Kinoshita E, Kinoshita-Kikuta E, Koike T: FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol. 2008, 15: 1138-1146. 10.1038/nsmb.1504PubMed CentralView ArticlePubMed
- Shu HG, Brown A, Yoon Y, Gao H, Purcell J, Snyder JP, Liotta DC, Shim H: Radiosensitization of glioma cells with the curcumin analogs EF24 and UBS109. AACR 99th Annual Meeting. 2008
- Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK: Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007, 25: 197-206. 10.1038/nbt1284View ArticlePubMed
- Yang K, Bai H, Ouyang Q, Lai L, Tang C: Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol. 2008, 4: 228- 10.1038/msb.2008.60PubMed CentralView ArticlePubMed
- Gage BM, Alroy D, Shin CY, Ponomareva ON, Dhar S, Sharma GG, Pandita TK, Thayer MJ, Turker MS: Spontaneously immortalized cell lines obtained from adult Atm null mice retain sensitivity to ionizing radiation and exhibit a mutational pattern suggestive of oxidative stress. Oncogene. 2001, 20: 4291-4297. 10.1038/sj.onc.1204509View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.